Dublin, Sept. 27, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/k3qxwk/pain_management)
has announced the addition of the
"Pain Management Treatment Markets" report to their
offering.
Pain management describes a particular set of drugs, analgesics,
which are specifically used as therapeutics to control pain in the
clinic. As pain affects 1.5 billion people worldwide, these drugs
are one of the major segments of the central nervous system (CNS)
therapies market.
This report focuses on the role of
pain management drugs in clinical use and in drug development
for acute pain, chronic pain, neuropathic path and nociceptive
pain. The research discusses drug development and targeted
therapeutics, as well as their use in clinical trials. New
approaches meant to aid in development of drugs for therapeutic use
are emphasized.
The study also analyzes almost all of the major, specialty and
emerging companies known to be marketing, manufacturing or
developing pain management treatment products in the U.S. and
worldwide. Additionally, this review provides detailed tables,
charts and figures with past and projected sales data for the U.S.,
Europe and other geographic regions.
Key Topics Covered:
1. Overview
2. Introduction
3. Market Overview
4. Pipeline Analysis
4.1 Introduction
4.2 Pain
4.3 Neuropathic Pain
4.4 Novel Therapeutic Approaches
4.5 Unsuccessful Targets
4.6 Novel Formulations
5. The Changing Competitive Landscape
5.1 Overview
5.2 The Exit of Major Companies
5.3 Major Pharma Players
5.4 Pain Specialty Companies
5.5 Emerging Biotechs
6. Market Outlook
6.1 Overview
6.2 Increased Demand
6.3 The Continued Impact of Generics
6.4 Key Patent Expirations
6.5 Key New Launches
6.6 Overall Assessment
6.7 Market Forecast
6.8 Geographical Analysis
7. Company Profiles
Companies Mentioned
- Abbott
- AcelRx
- Acura Pharmaceuticals
- Afferent Pharmaceuticals
- Algiax Pharmaceuticals
- Arcion Therapeutics
- Astellas
- BioDelivery Sciences International
- Cara Therapeutics
- Cephalon
- Convergence Pharmaceuticals
- Cytogel Pharma
- DURECT
- Egalet a/s
- Eli Lillya
- Emerging Biotechs
- Endo Pharmaceuticals
- Grunenthal
- Hospira
- Johnson & Johnson
- KemPharm
- Mallinckrodt
- NeurAxon
- NeurogesX
- Newron Pharmaceuticals
- Novartis
- Nuvo Research
- Pacira Pharmaceuticals
- Pain Specialty Companies
- Pain Therapeutics
- Pfizer
- Purdue Pharma
- QRx Pharma
- Relevare Pharmaceuticals
- Relmada Therapeutics
- Spinifex Pharma
- Xenon Pharma
- Xenoport
- Zalicus
- Zogenix
- iMed
For more information visit http://www.researchandmarkets.com/research/k3qxwk/pain_management
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals